"A Roadmap for MRD Testing in B-cell ALL" Webinar Series

Includes a Live Event on 12/09/2021 at 12:00 PM (EST)

This webinar is open to the public. You do not need to be an ACCC member to view this webinar, but you will need to create an account in order to register.  

If You DO NOT Have an ACCC Account:  

  • To start, click the green “Register” button in the upper right corner of this page. You will be directed to “Your Cart.” Click the green “Log In” button near the top of the page.  
  • ACCC and State Society Members: Click “Reset Password” to update your login information. When your password is updated, you will be redirected to the “My Profile” page.   
  • Non-members: Click “Create Account.” Once your password is created, you will be redirected to the "My Profile" page.   
  • Click “eLearning” at the top of your profile page to go back to the ACCC eLearning portal. In the box on the left side of the screen, click on the “Cart” link.  
  • The green box in the upper right corner of this page will indicate “You are registered!” for this course!

If You Have an ACCC Account: 

  • Please click the orange “Log In” button on the left side of this screen. You will be taken to the main login page that displays your email and password. Click the “Log in” button.  
  • You will be automatically redirected back to webinar page, and the green box in the upper right corner will say that “You are registered!” for this course!  

PRO TIP: If you save your ACCC password to your computer and remain logged in, you can register for additional webinars and courses in a matter of seconds—with just one click!   

For the best registration and viewing experience, please use Chrome, Edge, or Safari web browsers. Internet Explorer users may experience difficulties accessing the webinar. 

Once you complete your registration, you will receive an email from ACCC eLearning, which contains information on how to access this webinar. For assistance with registration or if you do not receive an email, please contact registration@accc-cancer.org.  

This three-part webinar series is aimed at building capacity to implement, expand, and sustain measurable residual disease (MRD) testing for patients with B-cell acute lymphoblastic leukemia (ALL) at cancer programs and practices of all resource levels.

When you register, you will automatically be registered for all three webinars. You will also receive access to all the on-demand recordings and slides once they become available.

A Roadmap for MRD Testing in B-cell ALL: Lay the Groundwork (Part I)

Thursday, November 18, 2021, 12:00 - 12:30 PM EST

Learn about the basics of MRD testing and how to assess your program’s buy-in to implement or expand MRD testing. 

Speakers 

  • Haifaa Abdulhaq, MD, Clinical Professor of Medicine, Hematology/Oncology Director of Hematology, UCSF Fresno 
  • Nikki Yuill, LCSW, Director, Information Resource Center, The Leukemia and Lymphoma Society (Moderator)

A Roadmap for MRD Testing in B-cell ALL: Prepare the Care Team (Part II) 

Thursday, December 2, 2021, 12:00 - 12:30 PM EST 

Learn how clinical and non-clinical staff are involved in MRD testing, how to assess your program’s communication and staffing needs, and how to develop an implementation plan.  

Speakers: 

  • Kelly Terrell, MBA, BSN, RN, BMTCN, Patient Care Manager, Operations, Division of Leukemia and Stem Cell Transplantation, Barnes-Jewish Hospital 
  • Nikki Yuill, LCSW, Director, Information Resource Center, The Leukemia and Lymphoma Society (Moderator) 

A Roadmap for MRD Testing in B-cell ALL: Implement the Initiative & Evaluate Your Progress (Part III) 

Thursday, December 9, 2021, 12:00 - 12:30 PM EST

Learn how to assess your clinical workflow needs to implement MRD testing and how to evaluate, pilot, and refine MRD testing in your program. 

Speakers: 

  • Rima Koka, MD, PhD, Associate Professor, University of Maryland School of Medicine; Associate Professor, Section of Hematology, Department of Pathology, University of Maryland Medical Center 
  • Nikki Yuill, LCSW, Director, Information Resource Center, The Leukemia and Lymphoma Society (Moderator) 


This webinar is open to the public. You do not need to be an ACCC member to view this webinar, but you will need to create an account in order to register. Please click the "Registration Instructions" tab for more details.

This webinar is part of the Integration of MRD Testing: A Pathway for Patients with B-Cell Acute Lymphoblastic Leukemia education project. Funding & support provided by Amgen.

Haifaa Abdulhaq, MD

Clinical Professor of Medicine, Hematology/Oncology Director of Hematology

UCSF Fresno

Haifaa Abdulhaq, M.D., is board certified in hematology and medical oncology with expertise in malignant hematology including lymphoproliferative neoplasms, myeloproliferative neoplasms, acute leukemia, multiple myeloma, and has an interest in stem cell transplantation.

Dr. Abdulhaq is a member of the American Society of Hematology, the American Board of Internal Medicine, the American Society of Clinical Oncology, and the American Society of Blood and Bone Marrow Transplantation. She is a board member of the Leukemia and Lymphoma Society, Central California Chapter, and she is the chair of the Cancer Committee at Community Medical Centers in Fresno, CA. Dr. Abdulhaq has special interest in medical education and is a recipient of the Henry Kaiser Award for Excellence in Teaching at UCSF. She is also interested in clinical research, and she serves as the principal investigator on many clinical trials on malignant hematology.

Dr. Abdulhaq completed a residency in internal medicine and a fellowship in hematology and oncology at Western Pennsylvania Hospital and Allegheny General Hospital in Pittsburgh, PA.

Rima Koka, MD, PhD

Associate Professor, University of Maryland School of Medicine; Associate Professor, Section of Hematology, Department of Pathology

University of Maryland Medical Center

As a pathologist, Madhurima Koka, MD, PhD, offers a unique perspective and new ideas on ongoing clinical trials based on her experience with morphology, immunophenotype, and molecular genetics. Furthermore, through her experience as a basic scientist, Dr. Koka learned the nuances of study design and data interpretation that allow for the application of scientific techniques to diagnosis and treat malignancies. She has particular interest in understanding the utility of molecular techniques in diagnosis and prognostication in lymphomas and leukemias. 

Dr. Koka works closely with hematologists and oncologists on various clinical-translational studies, which include the application of novel compounds in the treatment of acute leukemia and lymphomas. She is particularly interested in the use of immune-modulating agents and targeted immunotherapies in the treatment of these malignancies. Additionally, Dr. Koka is a co-investigator on a Bill & Melinda Gates Foundation-funded grant looking at the causes of childhood mortality in Mali, Africa. Dr. Koka has also provided pathologist support to numerous National Institutes of Health (NIH)-funded investigations through the University of Maryland cancer tissue repository.  

Kelly Terrell, MBA, BSN, RN, BMTCN

Clinical Program Manager, Division of Leukemia and Stem Cell Transplantation

Barnes-Jewish Hospital

Kelly Terrell, MBA, BSN, RN, BMTCN, is the nurse manager for the Stem Cell Transplant and Cell Therapy program at Barnes-Jewish Hospital at Washington University School of Medicine in St. Louis, Missouri.

She has nine years of experience in oncology, five of which have been in nursing leadership. Terrell has sat on several nurse advisory boards and has also had several abstracts published in the American Society of Hematology’s (ASH) peer-reviewed journal, Blood.

Kelly earned her bachelor of science degree from Goldfarb School of Nursing at Barnes-Jewish Hospital and her master of business administration degree from Webster University.

Nikki Yuill, LCSW (Moderator)

Director, Information Resource Center

The Leukemia & Lymphoma Society

Nikki Yuill is a bilingual (Spanish) Clinical Oncology Social Worker with more than 25 years of healthcare and oncology experience. She attended Purdue University in Indiana for her undergraduate degrees, and she completed her graduate work at the University of Texas at Austin.

Yuill has experience in blood cancers, solid tumors, andhematopoietic stem cell transplantation. She has extensive knowledge of and experience in advocacy, education, and support of blood cancer patients and their families. Yuill has a particular interest in adolescent and young adult cancer care, healthcare disparities, and serving the Latinx community.

Yuill is the director of the Information Resource Center at The Leukemia & Lymphoma Society (LLS), a global leader in the fight against cancer. LLS funds lifesaving blood cancer research around the world, provides free information and support services, and is the voice for all blood cancer patients seeking access to quality, affordable, coordinated care. Yuill is a proud member of the AOSW (Association of Oncology Social Workers). In 2020 she was awarded the AOSW LLS Oncology-Hematology Lifetime Achievement Award because of her longstanding efforts on behalf of cancer patients.

Key:

Complete
Failed
Available
Locked
Pre-Webinar Evaluation
1 Question
A Roadmap for MRD Testing in B-cell ALL: Lay the Groundwork
11/18/2021 at 12:00 PM (EST)   |  30 minutes
11/18/2021 at 12:00 PM (EST)   |  30 minutes Testing for measurable residual disease (MRD) can shape treatment choices and affect overall outcomes for patients with B-cell acute lymphoblastic leukemia (ALL). Unfortunately, routine MRD testing is variable. Join Dr. Abdulhaq for a practical, how-to discussion on laying the groundwork for MRD testing in your program, the first section in ACCC’s new MRD Testing Implementation Roadmap, an interactive, online tool intended to support cancer programs’ implementation and expansion of MRD testing. Learn about the basics of MRD testing and how to assess your program’s buy-in to implement or expand MRD testing.
Post-Webinar Evaluation
4 Questions
Pre-Webinar Evaluation
1 Question
A Roadmap for MRD Testing in B-cell ALL: Prepare the Care Team
12/02/2021 at 12:00 PM (EST)   |  30 minutes
12/02/2021 at 12:00 PM (EST)   |  30 minutes Testing for measurable residual disease (MRD) can shape treatment choices and affect overall outcomes for patients with B-cell acute lymphoblastic leukemia (ALL). Unfortunately, routine MRD testing is variable. Join Ms. Terrell for a practical, how-to discussion on preparing your care team to implement MRD testing, the second section of ACCC’s new MRD Testing Implementation Roadmap, an interactive, online tool intended to support cancer programs’ implementation and expansion of MRD testing. Learn how clinical and non-clinical staff are involved in MRD testing, how to assess your program’s communication and staffing needs, and how to develop an implementation plan.
Post-Webinar Evaluation
4 Questions
Pre-Webinar Evaluation
1 Question
A Roadmap for MRD Testing in B-cell ALL: Implement the Initiative & Evaluate Your Progress
12/09/2021 at 12:00 PM (EST)   |  30 minutes
12/09/2021 at 12:00 PM (EST)   |  30 minutes Testing for measurable residual disease (MRD) can shape treatment choices and affect overall outcomes for patients with B-cell acute lymphoblastic leukemia (ALL). Unfortunately, routine MRD testing is variable. Join Dr. Koka for a practical, how-to discussion on implementing and evaluating MRD testing in your program, the third and fourth sections of ACCC’s new MRD Testing Implementation Roadmap, an interactive, online tool intended to support cancer programs’ implementation and expansion of MRD testing. Learn how to assess your clinical workflow needs to implement MRD testing and how to evaluate, pilot, and refine MRD testing in your program.
Post-Webinar Evaluation
4 Questions